Search peptides — top sellers first
Search peptides — top sellers first
Search peptides — top sellers first
$119$11.90/mg
Synthetic GHRH analog — visceral adiposity and metabolic research
Buy 1, Get 1 Free · auto-applied
Add 2+ items to cart to activate the discount
Secure, encrypted checkout
Tesamorelin · 10mg
Frequently bought together
Researchers usually add these to complete the protocol.
BAC Water · 3ml
Essential · Extras
GHK-CU · 50mg
Recovery
Melanotan 2 · 10mg
Tanning
Certificate of analysis
We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.
Vantage Analytical
Independent analytical lab
Certificate of Analysis
RESULT · PASS
Analytical results
HPLC Chromatogram
Purity ≥98%
Know your compound
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that drives pulsatile GH secretion from the anterior pituitary. Sold pharmaceutically as Egrifta, it is the only GHRH analog to have completed an FDA-approval pathway, generating an unusually dense clinical dataset for a research peptide.
Phase 3 clinical trials documented 15–18% reductions in visceral adipose tissue (VAT) at 26 weeks in HIV-infected subjects — a selective effect that spared subcutaneous fat and did not perturb insulin sensitivity, a combination uncommon among lipolytic agents. Tesamorelin is also under active investigation in HIV-associated non-alcoholic fatty liver disease (NAFLD), where hepatic transcriptomic data suggest downstream effects on lipid-handling gene networks.
For research use only — not for human or veterinary use.
The research
The published findings behind this compound — the headline numbers, in plain terms, each cited to source. Preclinical results are directional (animal / in-vitro) and shown for context, not as therapeutic claims.
Published research on the reference compound class. Provided for scientific context only — not a claim about the product supplied.
In a Phase 3 randomized controlled trial in HIV-infected adults, tesamorelin reduced visceral adipose tissue by 15–18% over 26 weeks — a selective reduction that left subcutaneous fat statistically unchanged.
VAT change at 26 weeks, Phase 3 RCT — HIV-infected adults (Falutz et al., cited in Dhillon, Drugs 2011)
In the same Phase 3 trial, visceral fat fell meaningfully while subcutaneous fat remained statistically unchanged — a selective effect uncommon among lipolytic agents.
Relative magnitude of fat-depot response at 26 weeks — Phase 3 RCT, HIV-infected adults. Bar heights reflect directional contrast, not a shared absolute scale.
In HIV-infected adults, VAT reduction with tesamorelin was associated with improvements in triglycerides and broader metabolic markers versus placebo, with insulin sensitivity preserved throughout — suggesting a favorable cardiometabolic profile in this population.
Directional representation of triglyceride trajectory at 26 weeks — HIV-infected adults (Stanley et al., Clin Infect Dis 2012). Exact delta varies by endpoint; relative improvement shown.
In HIV-infected adults with NAFLD, tesamorelin was associated with differential expression of hepatic genes involved in lipid biosynthesis and inflammation versus placebo — suggesting downstream remodeling of liver lipid-handling pathways (Fourman et al., JCI Insight 2020).
HIV + NAFLD identified
Clinical unmet need
Tesamorelin studied
HIV-associated NAFLD cohort
Hepatic transcriptomics
Lipid & inflammation genes profiled
Differential expression
vs placebo — JCI Insight 2020
Fourman et al., JCI Insight 2020 — preliminary clinical findings; hepatic gene-network remodeling in HIV-infected adults with NAFLD.
Mechanism
Tesamorelin is studied to act through three distinct axes: pituitary GH secretion, downstream IGF-1 signaling, and selective visceral adipose tissue lipolysis.
Tesamorelin binds pituitary GHRH receptors and stimulates endogenous GH release in physiological pulses, preserving the pulsatile pattern associated with normal somatotropic signaling rather than producing a sustained supraphysiological GH surge.
GH released in response to tesamorelin drives hepatic IGF-1 production; researchers measure IGF-1 as the primary downstream biomarker of GHRH-axis engagement in clinical models, since IGF-1 mediates many of GH's metabolic effects at the tissue level.
Preclinical and clinical data indicate that GHRH-axis activation preferentially mobilizes visceral adipose tissue rather than subcutaneous depots, a depot-selectivity whose molecular basis — possibly related to GH-receptor density and receptor subtype expression — remains an active area of investigation.
For research use only. Mechanisms described reflect published preclinical and clinical literature.
The process
Synthesized
Produced under controlled manufacturing with documented, repeatable processes.
HPLC purity
An independent lab reports the exact purity of every lot — a number, never a 'passes'.
Mass-spec identity
Molecular weight confirms the exact sequence is what the label says.
COA published
The certificate is posted to the open library, by lot, before the vial ships.
Best sellers
FAQ
Common questions about Tesamorelin
The COA guarantee
Have any lot independently re-tested. If the results don't match the published certificate, we refund the order in full — no returns, no questions.
Order with coverThird-party tested
An independent, accredited lab — no commercial interest in the result.
A COA on every lot
A lot-specific certificate ships with each vial, archived by batch.
Test it yourself → refund
Re-test any batch at any lab. A mismatch is a full refund.
